Every 10-Q that OraSure Technologies Inc (OSUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OSUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSUR filings page.
OraSure Technologies reported Q2 2026 net revenues of $30.6 million, slightly below $31.2 million a year earlier, as flat sample management sales and higher syphilis and SickleSCAN revenues were offset by lower HCV, HIV and COVID-19 demand. Gross margin improved to 43.5% from 42.1%. A $22.6 million non-cash decrease in acquisition-related contingent consideration produced operating income of $5.4 million and net income of $6.2 million, versus a prior-year net loss of $19.7 million. For the first half, revenues were $58.6 million and the company recorded a net loss of $16.1 million.
Cash and cash equivalents were $160.6 million and working capital $197.8 million at June 30, 2026; management expects existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures over the next twelve months, despite $23.8 million of operating cash use in the first half. Contingent consideration liabilities fell from $27.7 million to $5.2 million after withdrawal of a CT/NG rapid molecular self-test submission, eliminating milestone obligations, while an impairment test concluded the related $17.0 million in-process R&D intangible asset was not impaired. During the period, OraSure obtained FDA clearance for its Colli-Pee Dx urine collection kit, Emergency Use Authorization for a second-generation OraQuick Ebola rapid antigen test, and repurchased $7.0 million of stock under its $40.0 million program.
OraSure Technologies (OSUR) filed its Q3 2025 10‑Q showing lower sales and wider losses. Net revenues were $27.085M (down 32% year over year), driven by declines in HIV diagnostics and Sample Management Solutions, plus the wind‑down of risk assessment testing and sharply lower COVID‑19 demand. Gross margin was 43.5%, slightly above last year on mix and higher non‑product revenue.
The company reported an operating loss of $16.1M and a net loss of $13.712M for the quarter. Research and development rose to $10.106M (up 80%) as clinical trials advanced for the CT/NG test acquired with Sherlock. For the nine months, net revenues were $88.258M (down 41%) with an operating loss of $51.866M.
Cash and cash equivalents were $216.478M at September 30, 2025 after a $51.285M year‑to‑date decrease, including $10.001M used to repurchase shares under a $40.0M authorization. Non‑product revenues increased on funded R&D tied to Sherlock and BARDA contracts. Subsequent to quarter‑end, the company signed an agreement to acquire BioMedomics for an upfront $4.0M in cash, plus contingent consideration.